PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Boehringer Ingelheim

Status: Completed

Conditions: Generalized Pustular Psoriasis

Treatments: Drug: Spesolimab

Study type: Observational

Funder types: Industry

Identifiers

NCT05670821

1368-0093

Details and patient eligibility

About

Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.) Infusion in Japan
• Patients who have never been treated with Spesolimab I.V. Infusion before enrolment

Exclusion criteria

• None

Trial design

52 participants in 1 patient group

Patients with generalized pustular psoriasis (GPP)

Treatment:

Drug: Spesolimab